Robin Jones to Drugs, Investigational
This is a "connection" page, showing publications Robin Jones has written about Drugs, Investigational.
Connection Strength
0.507
-
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Oct; 76(4):777-84.
Score: 0.507